Prior experience of morphine application alters the c-fos response to MDMA ('ecstasy') and cocaine in the rat striatum

Molecular Brain Research

Volumn 77, Issue 1, 2000, Pages 55-64

  Erdtmann Vourliotis, Martina ^a   Mayer, Peter ^a   Riechert, Uta ^a   Höllt, Volker ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

c fos; Co sensitization; Cocaine; In situ hybridization; LSD; MDMA; Morphine; THC

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; COCAINE; MORPHINE; MU OPIATE RECEPTOR;

ADDICTION; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG SENSITIZATION; GENE EXPRESSION; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; LOCOMOTION; NERVE CELL; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT;

ANIMALS; COCAINE; CORPUS STRIATUM; GENE EXPRESSION REGULATION; GENES, FOS; LYSERGIC ACID DIETHYLAMIDE; MALE; MORPHINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION, GENETIC;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0034646781     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00040-1     Document Type: Article

References (39)

1. Acquas E., DiChiara G. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58:1992;1620-1625.
2. Babbini M., Davis W.M. Time-dose relationship for locomotor activity effects of morphine after acute or repeated treatment. Br. J. Pharmacol. 46:1972;213-224.
3. Babbini M., Gaiardi M., Bartoletti M. Persistence of chronic morphine effects upon activity in rats 8 months after ceasing the treatment. Neuropharmacology. 14:1975;611-614.
4. Baca S.M., Lipska B.K., Egan M.F., Bachus S.E., Ferguson J.N., Hyde T.M. Effects of prefrontal cortical lesions on neuropeptide and dopamine receptor gene expression in the striatum-accumbens complex. Brain Res. 797:1998;55-64.
5. Bartoletti M., Gaiardi M., Gubellini G., Bacchi A., Babbini M. Long-term sensitization to the excitatory effects of morphine. Neuropharmacology. 22:1983;1193-1196.
6. Bloom F.E. Neurotransmission and the central nervous system. Hardman J.G., Goodman Gilman A., Limbird L.E. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 9th Edition :1996;557-577 McGraw-Hill, New York.
7. Carroll J.F. Uncovering drug abuse by alcoholics and alcohol abuse by addicts. Int. J. Addict. 15:1980;591-595.
8. Cunningham S.T., Finn M., Kelley A.E. Sensitization of the locomotor response to psychostimulants after repeated opiate exposure: role of the nucleus accumbens. Neuropsychopharmacology. 16:1997;147-155.
9. Curran E.J., Akil H., Watson S.J. Psychomotor stimulant- and opiate-induced c-fos mRNA expression patterns in the rat forebrain: comparisons between acute drug treatment and a drug challenge in sensitized animals. Neurochem. Res. 21:1996;1425-1435.
10. Erdtmann-Vourliotis M., Riechert U., Mayer P., Grecksch G., Höllt V. Pentylenetetrazole(PTZ)-induced c-fos expression in the hippocampus of kindled rats is suppressed by concomitant treatment with naloxone. Brain Res. 792:1998;299-308.
11. Erdtmann-Vourliotis M., Mayer P., Riechert U., Grecksch G., Höllt V. Identification of brain regions that are markedly activated by morphine in tolerant but not in naive rats. Mol. Brain Res. 61:1998;51-61.
12. Erdtmann-Vourliotis M., Mayer P., Riechert U., Händel M., Kriebitzsch J., Höllt V. Rational design of oligonucleotide probes to avoid optimization steps in in situ hybridization. Brain Res. Protocols. 4:1999;82-91.
13. Erdtmann-Vourliotis M., Mayer P., Riechert U., Höllt V. Acute injection of drugs with low addictive potential (D9-tetrahydrocannabinol, 3,4-methylenedioxymethamphetamine, lysergic acid diamide) causes a much higher c-fos expression in limbic brain areas than highly addicting drugs (cocaine and morphine). Mol. Brain Res. 71:1999;313-324.
14. Erdtmann-Vourliotis M., Mayer P., Linke R., Riechert U., Höllt V. Long-lasting sensitization towards morphine in motoric and limbic areas as determined by c-fos expression in rat brain. Mol. Brain Res. 72:1999;1-16.
15. Goldstein A. Addiction. From Biology To Drug Policy. 1993;Freeman, New York.
16. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology. 119:1995;247-260.
17. Höllt V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26:1986;59-77.
18. Hope B.T., Nye H.E., Kelz M.B., Self D.W., Iadarola M.J., Nakabeppu Y., Duman R.S., Nestler E.J. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1994;1235-1244.
19. Kaufman E. The relationship of alcoholism and alcohol abuse to the abuse of other drugs. Am. J. Drug Alcohol Abuse. 9:1982;1-17.
20. Lett B.T. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine and cocaine. Psychopharmacology. 98:1989;357-362.
21. 1 and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. USA. 91:1994;8537-8541.
22. Mansour A., Meador-Woodruff J.H., Bunzow J.R., Civelli O., Akil H., Watson S.J. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and in pituitary: an in situ hybridization-receptor autoradiographic analysis. J. Neurosci. 10:1990;2587-2600.
23. Mansour A., Meador-Woodruff J.H., Zhou Q.-Y., Civelli O., Akil H., Watson S.J. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiography and in situ hybridization techniques. Neuroscience. 45:1991;359-371.
24. Nestler E.J., Berhow M.T., Brodkin E.S. Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Mol. Psychiatry. 1:1996;190-199.
25. Nye H.E., Nestler E.J. Induction of chronic Fos-related antigens in rat brain by chronic morphine administration. Mol. Pharmacol. 49:1996;636-645.
26. O'Brien P. Drug addiction and drug abuse. Hardman J.G., Goodman Gilman A., Limbird L.E. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 9th Edition :1996;557-577 McGraw-Hill, New York.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd Edition :1997;Academic Press, San Diego.
28. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
29. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18:1993;247-291.
30. Rudnick G., Wall S.C. The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA. 89:1992;1817-1821.
31. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol. Biochem. Behav. 31:1988;817-824.
32. Schechter M.D. Candyflipping: synergistic discriminative effect of LSD and MDMA. Eur. J. Pharmacol. 341:1998;131-134.
33. Schuckit M.A., Bogard B. Intravenous drug use in alcoholics. J. Clin. Psychiatry. 47:1986;551-554.
34. Shippenberg T.S., LeFevour A., Thompson A.C. Sensitization to the conditioned rewarding effects of morphine and cocaine: differential effects of the kappa-opioid receptor agonist U69593. Eur. J. Pharmacol. 345:1998;27-34.
35. Spanagel R., Shippenberg T.S. Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat. Neurosci. Lett. 153:1993;232-236.
36. Spanagel R. Modulation of drug induced sensitization processes by endogenous opioid systems. Behav. Brain Res. 70:1995;37-49.
37. Stephenson C.P., Hunt G.E., Topple A.N., McGregor I.S. The distribution of 3,4-Methylenedioxymethamphetamine 'Ecstasy'-induced c-fos expression in rat brain. Neuroscience. 92:1999;1011-1023.
38. Vezina P., Kalivas P.W., Stewart J. Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist. DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res. 417:1987;51-58.
39. Wolf B., Grohmann R., Biber D., Brenner P.M., Ruther E. Benzodiazepine abuse and dependence in psychiatric inpatients. Pharmacopsychiatry. 22:1989;54-60.